

**TRIDENT LIFELINE LIMITED**

(Formerly Trident Lifeline Private Limited)

CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

October 29, 2026

BSE Limited 14th Floor, P. J. Towers, Dalal Street, Fort, Mumbai – 400001.	Stock ID: TLL Scrip Code: 543616 ISIN: INE0MKA01014
--	--

Dear Sir/Madam,

Sub: PRESS RELEASE FOR UNAUDITED FINANCIAL RESULTS FOR HALF YEAR ENDED SEPTEMBER 30, 2026

In terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, please find enclosed herewith a copy of Press Release for the Unaudited Financial results for the half year ended September 30, 2026.

Kindly take the above information on record.

Thanking you.

YOURS FAITHFULLY,
FOR TRIDENT LIFELINE LIMITED

NIKITA
SHARMA

Digitally signed by NIKITA
SHARMA
Date: 2026.10.29 13:27:44
+05'30'

NIKITA SHARMA
COMPANY SECRETARY AND COMPLIANCE OFFICER
M NO: A60595

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India.



Q2 FY27 COMMENTARY

HARDIK DESAI

CHAIRMAN &
EXECUTIVE DIRECTOR

Dear Shareholders,

Our vision has always extended beyond strengthening our core pharmaceutical formulations business. We believe that developing complementary businesses will create additional avenues for growth and enable us to build a more diversified healthcare platform with the potential to create long-term value. Guided by this vision, over the past decade we have consistently invested in manufacturing capabilities, regulatory approvals, infrastructure and new business verticals. These investments have laid the foundation for our current growth trajectory, and as our businesses scale and operational capabilities strengthen, we are beginning to realize the potential of the platform we have built.

As we enter the next phase, our priority is to translate these capabilities into sustained business growth. This will require continued focus on execution, expanding our market presence, strengthening our product portfolio and improving operational efficiencies. As our newer business verticals progress beyond their initial development and incubation stages, we expect their contribution to our consolidated performance to increase meaningfully over time.

Looking ahead, our aspiration remains to **triple our consolidated business over the next three years**. Achieving this ambition will depend on our ability to scale our business verticals successfully, execute our plans with discipline and allocate capital prudently. We remain committed to pursuing sustainable growth while creating enduring value for our shareholders over the long term.



Q2 FY27 COMMENTARY

ASHISH BAFNA

EXECUTIVE DIRECTOR &
CHIEF FINANCIAL OFFICER

Dear Shareholders,

Q2 FY27 has been encouraging for Trident Lifeline Limited, reflecting strong business growth, improved profitability, and continued progress towards our long-term strategic objectives.

Our consolidated revenue from operations grew by approximately **50%** to **₹47.1 crore**, compared with **₹31.3 crore** in the corresponding period last year. Consolidated profit after tax increased by approximately **30%** to **₹6.6 crore**, from **₹5.1 crore**.

On a standalone basis, revenue grew by approximately **19.3%** to **₹32.7 crore**, while profit after tax increased by approximately **33.1%** to **₹6.6 crore**, compared with **₹4.9 crore** in the previous corresponding period. These results reflect the growing scale of our business and our continued focus on profitable growth.

Our performance is supported by progress in product registrations, expansion into new markets, additions to our product portfolio, contributions from subsidiaries, and improving utilisation of our existing manufacturing capacities.

We are also progressing with the commissioning of our parenterals facility, which is expected to be commissioned after Diwali, subject to operational readiness. This will strengthen our manufacturing capabilities and support our future growth plans.

The proposed preferential issue will further strengthen our financial resources. The proceeds will support the Company's strategic priorities and provide a foundation for the next phase of expansion.

During the H2 FY27, our focus will remain on improving capacity utilisation, accelerating execution, expanding our product and market presence, strengthening subsidiary performance, and maintaining financial discipline.

Looking ahead, we remain committed to our ambition of tripling our consolidated business over the next three years. With our expanding platform, stronger execution capabilities, and disciplined approach to growth, we believe Trident Lifeline is well positioned to create sustainable long-term value for its shareholders.

Thank you for your continued trust and support.

INCOME STATEMENT

₹ crores unless otherwise mentioned

Particulars	Q2 FY27	Q2 FY26	YoY change	Q1 FY27	QoQ change	Q4 FY26	Q3 FY26	FY26
Revenue	47.1	31.3	50%	33.7	40%	50.0	25.7	129.0
EBITDA	11.3	6.9	65%	8.5	33%	11.0	5.1	28.1
EBITDA margin (%)	24.1%	21.9%	217 bps	25.3%	(120 bps)	22.0%	19.8%	21.8%
PAT	6.6	5.1	30%	5.1	30%	6.8	4.6	19.3
PAT margin (%)	14.0%	16.2%	(224 bps)	15.0%	(102 bps)	13.6%	18.1%	15.0%

About Trident Lifeline Limited:

Trident Lifeline Limited (“Trident Lifeline” or the “Company”) is a pharmaceutical and healthcare company with expertise in manufacturing finished dose pharmaceutical products, with a growing presence across global markets. The Company offers a diversified portfolio spanning pharmaceuticals, nutraceuticals, herbal products, injectables, personal care and medical devices, catering to a broad range of healthcare needs. Its operations are supported by a hybrid manufacturing model combining strategic manufacturing partnerships with integrated capabilities, enabling scalability, product quality and supply reliability. Trident Lifeline focuses on delivering quality-led healthcare solutions across domestic and international markets, supported by regulatory-compliant manufacturing capabilities, an expanding product portfolio and an established global distribution network.

Contact us:

Company



Trident Lifeline Limited

Nikita Sharma

Company Secretary

compliance@tridentlifeline.com

Investor relations consultant



NeoAtlas Capital Advisory LLP

Preet Choradiya

+91 7383201103 | research@atlascapital.in

Rutul Shah

+91 8200247366 | rutul.shah@atlascapital.in

Meeting Request



Safe harbor - Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Trident Lifeline Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.